STOCK TITAN

Revvity, Inc. - RVTY STOCK NEWS

Welcome to our dedicated page for Revvity news (Ticker: RVTY), a resource for investors and traders seeking the latest updates and insights on Revvity stock.

Revvity, Inc. (RVTY) is a leading company dedicated to enhancing human and environmental health. The company collaborates with scientists, clinicians, and government agencies to develop more effective diagnostics and therapies. Additionally, Revvity ensures the safety of our food and air by detecting contaminants that could harm the environment and public health.

Revvity operates under two main segments: Diagnostics and Discovery & Analytical Solutions. The Diagnostics segment focuses on areas such as immunodiagnostics, reproductive health, and applied genomics. This division provides crucial tools and tests for genetic screening and various health diagnostics. Meanwhile, the Discovery & Analytical Solutions segment addresses life science research and industrial applications, offering products and services for environmental and food analysis, as well as informatics and enterprise software solutions.

In recent achievements, Revvity has been at the forefront of developing innovative solutions that transform raw data into actionable insights, thus improving public health and environmental safety. The company’s systems are instrumental in rapidly detecting both known and unknown contaminants in food, water, and air. They also play a critical role in ensuring compliance with health and safety standards.

Revvity's partnerships span across the pharmaceutical, biomedical, chemical, environmental, and industrial markets, making it a versatile player in multiple sectors. The company’s commitment to quality and innovation has led to significant advancements in research and diagnostics, making it a key contributor to global health and safety.

Rhea-AI Summary

Revvity (NYSE: RVTY) has announced its participation in two upcoming investor conferences in September 2024. The company will present at the 2024 Wells Fargo Healthcare Conference in Boston on September 4, with CFO Max Krakowiak speaking at 8:45 a.m. ET. Additionally, Revvity will attend the 2024 Baird Global Healthcare Conference in New York City on September 10, where Steve Willoughby, SVP of investor relations, ESG, and risk, will present at 12:15 p.m. ET.

Both presentations will provide updates on Revvity's strategic priorities and will be available via live audio webcasts on the company's website. Replays will be accessible for at least 30 days after the events on the Revvity Investor Relations website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.03%
Tags
conferences
-
Rhea-AI Summary

Revvity reported Q2 2024 financial results with revenue of $692 million, down 2% reported and 1% organic. GAAP EPS was $0.45, up from $0.28 year-over-year, while adjusted EPS from continuing operations was $1.22, slightly up from $1.21. The company raised its full-year 2024 adjusted EPS guidance to $4.70-$4.80.

Segment performance varied: Life Sciences revenue decreased 7% to $314 million, with adjusted operating margin at 35.8%. Diagnostics revenue increased 1% to $378 million, with adjusted operating margin improving to 25.9%. Revvity updated its full-year revenue guidance to $2.77-$2.79 billion, assuming 2% organic growth.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.07%
Tags
-
Rhea-AI Summary

Revvity's Board of Directors has declared a quarterly dividend of $0.07 per share of common stock. This dividend will be paid on November 8, 2024, to shareholders of record at the close of business on October 18, 2024. Revvity, traded on the New York Stock Exchange under the ticker symbol RVTY, continues its practice of rewarding shareholders through regular dividend payments. This announcement demonstrates the company's commitment to providing consistent returns to its investors, even as it navigates the current economic landscape.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.07%
Tags
dividends
Rhea-AI Summary

Revvity (NYSE: RVTY) will announce its Q2 2024 financial results on July 29, 2024, before the market opens. A conference call hosted by CEO Prahlad Singh and CFO Max Krakowiak will follow at 8:00 a.m. ET to discuss the results. Investors can access the live audio webcast via the company's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.6%
Tags
-
Rhea-AI Summary

Revvity (NYSE: RVTY) will present at the 45th Annual Goldman Sachs Global Healthcare Conference on June 10, 2024, at 8:00 a.m. ET in Miami, FL. The event will feature Prahlad Singh, the president and CEO of Revvity, who will provide an update on the company's strategic priorities. A live audio webcast and a replay of the presentation will be available on the company's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.24%
Tags
conferences
-
Rhea-AI Summary

Revvity, Inc. (NYSE: RVTY) reported financial results for the first quarter ended March 31, 2024, revealing a (4)% reported growth and a (3)% organic growth in revenue, with GAAP EPS of $0.21, compared to the same period last year. Adjusted EPS was $0.98, reaffirming full year 2024 organic growth and adjusted EPS guidance. It's important to note that the company's adjusted operating income and profit margins have decreased compared to the same period last year. The company will provide a live webcast on April 29, 2024, to discuss the results.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.46%
Tags
Rhea-AI Summary
Revvity (RVTY) Board announces a regular quarterly dividend of $0.07 per share of common stock payable on August 9, 2024, to shareholders of record as of July 19, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.57%
Tags
dividends
-
Rhea-AI Summary
Revvity, Inc. (NYSE: RVTY) is set to present at the BofA Securities 2024 Health Care Conference on May 14, 2024. Senior Vice President and CFO Max Krakowiak will discuss the Company's strategic priorities. The presentation will be live-streamed on Revvity's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.57%
Tags
conferences
-
Rhea-AI Summary
Revvity, Inc. (NYSE: RVTY) unveils the Auto-Pure 2400 liquid handler for use with the T-SPOT.TB test, revolutionizing tuberculosis testing. The new system substantially reduces hands-on time, boosting lab productivity. Labs, clinicians, and patients benefit from the efficient workflow and clinical accuracy of the combined solution.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.79%
Tags
none
Rhea-AI Summary
Revvity, Inc. (NYSE: RVTY) introduces Signals SynergyTM, a software solution enhancing collaboration between pharmaceutical and biotechnology sponsors and their contract partners. Signals Synergy aims to streamline processes, improve data stewardship, and reduce errors and delays in project management.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.13%
Tags
none

FAQ

What is the current stock price of Revvity (RVTY)?

The current stock price of Revvity (RVTY) is $111.34 as of November 20, 2024.

What is the market cap of Revvity (RVTY)?

The market cap of Revvity (RVTY) is approximately 13.5B.

What does Revvity, Inc. specialize in?

Revvity specializes in improving human and environmental health through diagnostics, therapies, and contaminant detection.

What are the main segments of Revvity?

Revvity operates under two main segments: Diagnostics and Discovery & Analytical Solutions.

What services does Revvity provide?

Revvity provides instruments, tests, services, and software solutions for pharmaceutical, biomedical, chemical, environmental, and industrial markets.

How does Revvity contribute to environmental health?

Revvity helps detect contaminants in food, water, and air, ensuring compliance with health and safety standards.

What recent achievements has Revvity made?

Revvity has developed innovative solutions that transform data into actionable insights, improving public health and safety.

What industries does Revvity serve?

Revvity serves pharmaceutical, biomedical, chemical, environmental, and general industrial markets.

What are some key products offered by Revvity?

Key products include genetic screening tools, environmental analytical instruments, and informatics software.

How does Revvity support life science research?

Revvity provides life science research instrumentation and diagnostic lab services to advance health and scientific understanding.

Who are Revvity's primary partners?

Revvity partners with scientists, clinicians, government agencies, and industries to improve diagnostics and environmental health.

How does Revvity ensure the safety of food and air?

Revvity uses advanced systems to detect contaminants and monitor the quality of food and air, ensuring compliance with safety standards.

Revvity, Inc.

NYSE:RVTY

RVTY Rankings

RVTY Stock Data

13.47B
121.36M
0.29%
91.94%
3.44%
Diagnostics & Research
Laboratory Analytical Instruments
Link
United States of America
WALTHAM